Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Position Decreased by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 23.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,245 shares of the biopharmaceutical company’s stock after selling 669 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Intra-Cellular Therapies were worth $188,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after acquiring an additional 2,157 shares in the last quarter. Barclays PLC increased its position in Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after buying an additional 25,435 shares during the last quarter. Oak Ridge Investments LLC raised its holdings in Intra-Cellular Therapies by 74.1% during the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after buying an additional 8,440 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock worth $43,735,000 after buying an additional 18,865 shares during the last quarter. Finally, Merit Financial Group LLC bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $206,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

ITCI opened at $131.87 on Friday. The stock’s 50 day simple moving average is $129.62 and its 200-day simple moving average is $101.43. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ITCI has been the topic of a number of recent analyst reports. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price objective for the stock from $119.00 to $132.00 in a report on Friday, January 31st. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a report on Saturday. They issued a “hold” rating on the stock. Finally, Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $140.00 to $132.00 in a report on Monday, February 24th. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.